Isoliquiritigenin Impedes Breast Cancer Progression through PITX1-PFKP-Mediated Glycolysis Reprogramming.

Area of Science:

• Oncology
• Molecular Biology
• Metabolic Pathways

Background:

• Breast cancer metastasis is a leading cause of cancer mortality in women.
• Metabolic reprogramming is crucial for tumor growth and spread, but its role in breast cancer metastasis is not fully understood.
• Identifying molecular targets and therapeutic strategies for breast cancer progression is critical.

Purpose of the Study:

• To identify key metabolic regulators involved in breast cancer progression.
• To investigate the role of Paired Like Homeodomain 1 (PITX1) in breast cancer metastasis.
• To evaluate targeting metabolic reprogramming as a therapeutic strategy for breast cancer.

Main Methods:

• Analysis of high-throughput RNA sequencing data to identify key regulators.
• Validation of PITX1 expression using immunohistochemistry, qPCR, and western blotting.
• Functional assays to assess the impact of PITX1 on breast cancer proliferation and metastasis, including mechanistic studies on the PITX1-PFKP axis.

Main Results:

• Elevated PITX1 expression correlates with poorer patient survival and increased metastasis.
• Silencing PITX1 reduces breast cancer cell proliferation and suppresses glycolysis.
• PITX1 transcriptionally activates Phosphofructokinase platelet (PFKP), enhancing glycolytic flux and promoting tumor growth and metastasis.

Conclusions:

• PITX1 promotes breast cancer progression and metastasis via glycolytic reprogramming.
• The PITX1-PFKP axis is a novel oncogenic mechanism in breast cancer.
• Isoliquiritigenin, a small-molecule inhibitor, targeting the PITX1-PFKP axis shows promise for breast cancer treatment.